Inspire Medical Systems Earnings Preview: Analyst Estimates and Historical Performance
PorAinvest
sábado, 2 de agosto de 2025, 2:49 am ET1 min de lectura
INSP--
Historically, Inspire Medical Systems has a track record of beating EPS estimates. In the last reported quarter, the company delivered an EPS surprise of +143.48%, beating expectations by $0.33 [1]. This performance was followed by a 1.98% increase in share price the next day. Over the last four quarters, the company has beaten consensus EPS estimates four times.
Analysts have given Inspire Medical Systems a consensus rating of Outperform, with an average one-year price target of $197.33, suggesting a potential 58.45% upside [2]. The company ranks at the top for revenue growth and gross profit among its peers, but it has the lowest return on equity [2].
Inspire Medical Systems operates as a medical technology company, focusing on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). The company's Inspire system is a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.
The company's market capitalization is positioned below industry averages, which could be attributed to factors such as growth expectations or operational capacity [2]. Revenue growth for the company was approximately 22.75% as of 31 March 2025, indicating a notable increase in top-line earnings.
Investors should pay attention to other factors beyond the earnings beat or miss, as these are not the sole determinants of a stock's performance. The company's Earnings ESP of +9.09% and Zacks Rank of #3 suggest that Inspire is likely to beat the consensus EPS estimate [1]. However, the sustainability of the immediate price change and future earnings expectations will depend on management's discussion of business conditions on the earnings call.
References:
[1] https://finance.yahoo.com/news/inspire-medical-systems-insp-expected-140013342.html
[2] https://www.benzinga.com/insights/earnings/25/08/46800844/uncovering-potential-inspire-medical-systemss-earnings-preview
Inspire Medical Systems is set to announce its quarterly earnings on August 4, 2025. Analysts estimate an EPS of $0.21. Historically, the company has beaten EPS estimates and seen a 1.98% increase in share price. Inspire Medical Systems has received a total of 6 ratings from analysts, with a consensus rating of Outperform and a potential 58.45% upside.
Inspire Medical Systems (INSP) is set to announce its quarterly earnings on August 4, 2025. Analysts estimate an EPS of $0.21, which represents a year-over-year decline of -31.3% [1]. While revenues are expected to increase by 9.8% to $215.05 million, the earnings outlook indicates a challenging quarter for the company.Historically, Inspire Medical Systems has a track record of beating EPS estimates. In the last reported quarter, the company delivered an EPS surprise of +143.48%, beating expectations by $0.33 [1]. This performance was followed by a 1.98% increase in share price the next day. Over the last four quarters, the company has beaten consensus EPS estimates four times.
Analysts have given Inspire Medical Systems a consensus rating of Outperform, with an average one-year price target of $197.33, suggesting a potential 58.45% upside [2]. The company ranks at the top for revenue growth and gross profit among its peers, but it has the lowest return on equity [2].
Inspire Medical Systems operates as a medical technology company, focusing on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). The company's Inspire system is a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.
The company's market capitalization is positioned below industry averages, which could be attributed to factors such as growth expectations or operational capacity [2]. Revenue growth for the company was approximately 22.75% as of 31 March 2025, indicating a notable increase in top-line earnings.
Investors should pay attention to other factors beyond the earnings beat or miss, as these are not the sole determinants of a stock's performance. The company's Earnings ESP of +9.09% and Zacks Rank of #3 suggest that Inspire is likely to beat the consensus EPS estimate [1]. However, the sustainability of the immediate price change and future earnings expectations will depend on management's discussion of business conditions on the earnings call.
References:
[1] https://finance.yahoo.com/news/inspire-medical-systems-insp-expected-140013342.html
[2] https://www.benzinga.com/insights/earnings/25/08/46800844/uncovering-potential-inspire-medical-systemss-earnings-preview
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios